Introduction
The identification of Gala1,3Gal (Gal) as the major target antigen for human and nonhuman primate (NHP) antipig antibodies and the production of a1,3-galactosyltransferase gene-knockout (GTKO) pigs [1] have helped to resolve the problem of hyperacute rejection. However, acute humoral xenograft rejection, chronic rejection, and other barriers to success, for example, coagulation dysregulation in the form of thrombotic microangiopathy and/ or consumptive coagulopathy, need to be addressed if graft survival is to be significantly prolonged.
The initial studies in which kidneys [2] and hearts [3] from GTKO pigs were transplanted into NHPs had encouraging results, but used immunosuppressive regimens that are unlikely to be used clinically. New strategies should be aimed toward extending xenograft survival, minimizing the side-effects of the immunosuppressive agents, and enabling clinical trials to be considered. Extensive reviews of xenotransplantation in pig-to-NHP models have been reported [4 ,5] . The current review summarizes the most recent results of solid organ xenotransplantation using GTKO pig organs (with or without additional genetic modifications) in the pig-to-NHP model in combination with novel therapeutic approaches.
Heart xenotransplantation
Experimental heart xenotransplantation can be performed using three different techniques: heterotopic intraabdominal model, heterotopic intrathoracic model, and orthotopic model (Table 1) [6 ,7,8,9 ,10,11 ,12,13 ] . Ezzelarab et al. [9 ] demonstrated that costimulation blockade with an anti-CD154 mAb prolonged graft survival, but early or late xenograft failure was associated with activation of the innate immune system. Consumptive coagulopathy occurred in six of nine recipients. Using the same model and immunosuppression as Ezzelarab et al. [9 ] , Burdorf et al. [7] concluded that a high pretransplantation level of antinonGal antibodies limited the efficacy of costimulation blockade. There is clearly a need for alternative or adjunct therapies to control the humoral response.
Brenner et al. [10] transplanted hearts from GTKO, GTKO/CD46, or GTKO/HO-1 (heme oxygenase-1) pigs. There was no difference in median survival in relation to the various genotypes of the organ-source pig, but extended survival was achieved when immunoadsorption was carried out.
The identification of major antinonGal antibodies and development of strategies to reduce the corresponding antigens on the pig [16] may lead to prolonged survival.
Heterotopic intrathoracic model
Bauer et al. [12] employed the original Losman and Barnard technique of intrathoracic heterotopic heart transplantation [17] . This would be a clinically applicable approach because, in view of the continuing presence of the recipient's native heart, graft failure would not necessarily result in death of the patient [12] . They reported two cases using GTKO/CD46 pig hearts in baboons and incorporated pretransplantation immunoadsorption of antipig antibody in the recipient. The first recipient died within hours from air embolism and brain damage, whereas the second graft functioned for 50 days.
Orthotopic model
McGregor et al. [13 ,18] reported orthotopic heart transplantation of GTKO/CD55 pig hearts into baboons using a clinically applicable immunosuppressive regimen (Table 1) . Longest survival was 57 days (with good cardiac function), which is the longest reported to date, and median survival was 28.5 days.
Kidney xenotransplantation
In a nonimmunosuppressed pig-to-monkey model, an Australian group showed that the combination of GTKO with expression of CD55/CD59/HT (H-transferase) improved renal xenograft survival and delayed or prevented the development of consumptive coagulopathy (Table 2) [6 ,7,9 ,19 ,20-23,24 ,25] .
Under the Xenome Project of the European Union, pigs with multiple genetic modifications (GTKO/CD55/ CD39/HT) were transplanted into NHPs. Cozzi et al. in cynomolgus monkeys [19 ] and Le Bas-Bernardet et al.
in baboons [21] reported similar outcomes using different clinically applicable immunosuppressive regimens. In the experience of Cozzi et al. [19 ] , multiple genetic modifications were not associated with prolonged recipient survival, though preliminary coagulation data were consistent with a lower extent of coagulopathy when compared with previous studies using pigs expressing CD55 on a wild-type background. They drew attention on the presence of CD20 þ infiltrating cells in the majority of the grafts, which correlates with Mohiuddin's experience that the addition of a B cell-depleting agent to the immunosuppressive regimen is beneficial.
The longest survivals of baboons with life-saving pig kidney grafts were reported by the Boston group in their thymokidney transplantation models [20, 25] . Griesemer et al. [20] performed seven GTKO pig-to-baboon thymokidney transplants. Median survival was 49 days, with the longest survival being 83 days. This baboon was the only one that received whole body radiation and appears to have been reported previously [2] . Several immunosuppressive regimens, including different T cell-depleting (antithymocyte globulin or monoclonal mouse antihuman CD2b antibody) and B cell-depleting (anti-CD20 mAb) agents were tested. The kidney grafts showed no signs of cellular infiltration or deposition of IgG, and no grafts were lost from rejection. In the same thymokidney model, the same group reported that high levels of preformed cytotoxic antinonGal antibody did not induce hyperacute rejection, but were associated with early graft loss [25] , correlating with the observations of Burdorf et al. [7] .
With the goal of inducing transplantation tolerance, the Boston group performed GTKO pig-to-baboon renal xenotransplants using an extensive immunosuppressive regimen combined with GTKO pig bone marrow administration [23] . Two baboons received kidney transplants 2 or 17 days after bone marrow administration. One baboon died from renal failure (day 8) and the other developed thrombocytopenia and consumptive coagulopathy and expired with pulmonary edema after 24 days.
Burdorf et al. [7] reported kidney transplants in baboons from GTKO, GTKO/CD55, and GTKO/CD46 pigs. Various immunosuppressive regimens included T-cell depletion and costimulation blockade. Prolonged survival was achieved with GTKO/CD55 and GTKO/CD46 pigs when compared to GTKO pigs. They observed the same outcomes as in their heart xenotransplantation model in that a high pretransplant level of antinonGal antibodies was associated with a substantial incidence of early graft failure. This antibody response has been reviewed by others [16, 26] .
Ezzelarab et al. [9 ] reported that the GTKO genetic modification alone with depletion of complement activity in the recipient by cobra venom factor was not enough to prevent acute humoral xenograft rejection and/or consumptive coagulopathy. Lin et al. [24 ] studied the role of tissue factor expression on circulating platelets and peripheral blood mononuclear cells (PBMCs) following either GTKO or GTKO/CD46 pig kidney transplantation in baboons. Tissue factor was detected on platelets on posttransplant day 1, but was not detected on PBMCs until consumptive coagulopathy was beginning to develop. Graft histopathology showed fibrin deposition and platelet aggregation (n ¼ 6), but with only minor features indicating a humoral immune response, and no macrophage, B-or T-cell infiltration. Prevention of recipient platelet activation will be critical for successful pig kidney transplantation.
Liver xenotransplantation
The first and only xenotransplantations using GTKO pig livers came from the Pittsburgh group [27 ] , who reported 10 liver xenotransplants from GTKO or GTKO/CD46 pigs using a clinically applicable immunosuppressive regimen. The importance of size matching between pig liver and recipient baboon was emphasized. The narrow abdomen of baboons necessitated the use of livers from pigs that were almost 60% smaller in weight than the recipient baboon. Six of 10 baboons survived for 4-7 days. No obvious difference was observed between GTKO and GTKO/CD46 pig livers. In all cases, liver function was adequate, as evidenced by tests of detoxification, complement activity, coagulation parameters, and production of pig proteins, including coagulation factors [28 ] . Pig coagulation factors and proteins appeared to function adequately in baboons, although interspecies compatibility of such proteins remains to be confirmed (Table 3) .
Survival beyond 7 days was prevented by a profound thrombocytopenia that developed within 1 h after reper-fusion of the graft, ultimately resulting in spontaneous hemorrhage at various sites [27 ] . The authors postulated that the thrombocytopenia was associated with the expression of tissue factor on platelets after contact with the pig endothelium, resulting in platelet and platelet-PBMC aggregation and deposition of aggregates in the liver graft, although phagocytosis of the platelets by pig Kupffer cells or hepatocytes could not be ruled out.
The Pittsburgh study was primarily undertaken to determine whether the pig liver could be used as a bridge to allotransplantation in patients with fulminant liver failure. Bridging options, and inclusion and exclusion criteria have been discussed [29 ] . The immediate development of thrombocytopenia needs to be prevented before a clinical trial would be justified.
Coagulation dysregulation
Three review papers discussed this topic [30 ,31 ,32] and are reviewed elsewhere in this issue by Cowan et al. [33] . The need for pigs expressing one or more human 'thromboregulatory' genes, such as tissue factor pathway inhibitor (TFPI) or human thrombomodulin, is crucial. Two attempts using CD39 pig kidneys have been reported (Table 2) , but adequate expression of CD39 was doubtful [19 ,21] . The effect of expression of a thomboregulatory gene or genes, therefore, remains untested. There are several pharmacologic agents that would likely prove beneficial, for example, heparin, aspirin, ketorolac, and prostacyclin (Tables 1-3 ), but which interventions will be beneficial, yet effective and safe, also remains uncertain [30 ,32] .
The discrepancies between the results reported by various groups with regard to the development of coagulopathy cannot be fully explained, though a number of factors may be playing roles, for example, differences in the source of the pigs, the immunosuppressive regimen, and the organ transplanted. The literature suggests that the development of consumptive coagulopathy is less common or delayed when intensive immunosuppressive therapy is administered [34] , though the exact mechanism of this effect remains uncertain. It is well known that the costimulation blockade agent, anti-CD154 mAb, is associated with thromboembolic events [35] [36] [37] , and it is possible that this may be a factor in some of the reported studies, though thrombotic microangiopathy develops in NHPs receiving conventional immunosuppressive therapy [34] . Our experience of transplanting GTKO pig organs does not indicate to us that the GTKO genetic modification increases the 'thrombogenicity' of the organ graft. However, Knosalla et al. [38 ] have reported that there is a clear heterogeneity between renal and cardiac xenograft endothelium, which may account for the observed increased incidence of consumptive coagulopathy after pig kidney xenotransplantation.
Complement regulation
Miyagawa et al. [39 ] published a valuable review on complement regulation in the GTKO era. After GTKO pig organ xenotransplantation, complement is activated by the classical pathway, by the interaction of antinonGal antibodies and non-Gal antigens, and by ischemic injury; the alternative pathway, especially after pig islet transplantation; and the lectin pathway. The complement system represents an important recognition and effector mechanism of acute humoral xenograft rejection. The various CRPs, for example, CD35, CD46, CD55, CD59, C1-inhibitor, regulate complement activation at different points in the complement cascade. Therefore, it will be preferable to express multiple human CRP genes in GTKO pigs rather than rely on a single gene.
Cowan and d'Apice [32] emphasized the importance of antinonGal antibodies in the humoral response to a GTKO pig organ. Without complete suppression of production of these antibodies, there is progressive activation and injury of the graft endothelium, resulting in thrombotic microangiopathy, with subsequent graft loss [31 ] .
The potential role of cytotherapy
Cytotherapy [e.g., the infusion of bone marrow, T-regulatory cells, or mesenchymal stem cells (MSCs)] to the recipient of a solid organ xenograft could be beneficial [23] . In their quest for microchimerism, Griesemer et al. [23] administered GTKO bone marrow to baboons. Of the four baboons, two received pig kidney transplants, with no significant prolongation of graft survival compared to that in baboons that did not receive bone marrow (summarized above).
Although there are several different subtypes of T-regulatory cells, CD4 þ CD25 þ Foxp3 þ T cells are the most characterized and have been suggested as an immunosuppressive strategy in xenotransplantation [40 ,41 ,42] . Although in-vitro studies show expanded T-regulatory cells inhibit the baboon cellular response to pig PBMCs, the effect on prolongation of xenograft survival needs confirmation in NHP studies [43] . In contrast to cadaveric allotransplantation, the organ donor is known prior to xenotransplantation, which should facilitate therapy with T-regulatory cells.
The report of successful treatment of severe graftversus-host disease after clinical bone marrow transplantation by MSCs created substantial interest [44] . dendritic cell maturation, and induce T-regulatory cells, and hence may prove a potential therapy for solid organ transplantation. Ezzelarab et al. [45] discussed the potential of (organ) donor-specific genetically modified pig MSCs.
MSCs prohibit the proliferation of T cells, inhibit

Future directions
Five years after the first results of GTKO pig-to-NHP organ transplantation were reported, the addition to GTKO of one or more human CRPs has been associated with better outcomes. The expression of multiple CRPs is probably preferable. Antithrombotic gene expression is required to reduce coagulation dysregulation. Pigs with potential resistance to the human cellular response are also becoming available. Stimulatory and inhibitory receptor interactions in xenotransplantation have been reviewed elsewhere [56] . The production of human Fas ligand-expressing pigs, which may prevent human CD8 þ and natural killer cell cytotoxicity, has recently been reported [48 ] . With the aim of protecting against injury by natural killer cells, Weiss et al. [47] produced HLA-E/human beta2-microglobulin-expressing pigs. Pigs expressing CTLA4-Ig have been produced so successfully that the level of CTLA4-Ig in the blood was several times higher than the therapeutic level [46 ] ; these pigs demonstrated features of immunoincompetence, for example, infections, and required euthanasia. Major histocompatibility complex (MHC) class II transactivator (CIITA) gene knock-down pigs have been generated (Dai Y et al., unpublished). In-vitro testing of the human CD4 þ T-cell response to cells from CIITA pigs indicated a much diminished human T-cell response, suggesting that organs and cells from these pigs should be significantly protected against the human/NHP cellular immune response [49 ] .
Other pigs that have become available include human HO-1-expressing pigs [51] and human A20-expressing pigs [50] . These will hopefully provide some antiapoptotic, anti-inflammatory, and cell protective effects. Porcine endogenous retrovirus siRNA-expressing transgenic pigs, aimed at preventing the activation and propagation of porcine endogenous retrovirus, have been produced [53, 54] .
Newer immunosuppressive and adjunctive agents, for example, anticoagulants, may also be beneficial. Alemtuzumab (anti-CD52 mAb) combined with mycophenolate mofetil depleted and maintained the number of CD4 þ cells at less than 25% for at least 1 year in cynomolgus 228 Xenotransplantation monkeys [57 ] and, therefore, may have a role in xenotransplantation.
Conclusion
In summary, the increasing number of genetic modifications being made to GTKO pigs [58] and more effective immunosuppressive, anticoagulant, and anti-inflammatory regimens provide the expectation of improved experimental results that may eventually lead to the initiation of clinical trials.
